Cellular and Molecular Immunology(CMI),the official journal of theChinese Society of Immunology,was established in 2004.CMI hasnow become one of the leading international journals in the fieldand publishes high-qualit...Cellular and Molecular Immunology(CMI),the official journal of theChinese Society of Immunology,was established in 2004.CMI hasnow become one of the leading international journals in the fieldand publishes high-quality original articles and reviews.The veryfirst research article published in the inaugural issue of CMI wasfrom our group and described,for the first time,the protectiveeffect of interleukin-22(IL-22)on the epithelium in the liver.1Fascinatingly,14 years later,the first-in-human phase I clinicalstudy of human IL-22-Fc dimer(F-652)in healthy subjects is alsopublished in CMI.2 We are very excited to see these interestingstudies of IL-22 from bench to bedside published in CMI alongsideits strong growth as a journal over the last 14 years.展开更多
The coronavirus disease 2019(COVID-19)has caused global public health and economic crises.Thus,new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic.The development of...The coronavirus disease 2019(COVID-19)has caused global public health and economic crises.Thus,new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic.The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is one of the attractive treatment strategies for COVID-19.Currently,the receptor-binding domain(RBD)of the spike(S)protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells.A single monoclonal antibody(mAb)treatment is prone to selective pressure due to increased possibility of targeted epitope mutation,leading to viral escape.In addition,the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection.These risks can be reduced using multiple mAbs that target nonoverlapping epitopes.Thus,a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.展开更多
基金the intramural program of the NIAAA and NIH(B.G.).
文摘Cellular and Molecular Immunology(CMI),the official journal of theChinese Society of Immunology,was established in 2004.CMI hasnow become one of the leading international journals in the fieldand publishes high-quality original articles and reviews.The veryfirst research article published in the inaugural issue of CMI wasfrom our group and described,for the first time,the protectiveeffect of interleukin-22(IL-22)on the epithelium in the liver.1Fascinatingly,14 years later,the first-in-human phase I clinicalstudy of human IL-22-Fc dimer(F-652)in healthy subjects is alsopublished in CMI.2 We are very excited to see these interestingstudies of IL-22 from bench to bedside published in CMI alongsideits strong growth as a journal over the last 14 years.
基金This study was supported by the National Natural Science Foundation of China(No.81970514)the Shanghai Municipal Key Clinical Specialty(No.shslczdzkOl 103)the Shanghai Municipal Planning Commission of Science and Research Fund(No.202040111).
文摘The coronavirus disease 2019(COVID-19)has caused global public health and economic crises.Thus,new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic.The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is one of the attractive treatment strategies for COVID-19.Currently,the receptor-binding domain(RBD)of the spike(S)protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells.A single monoclonal antibody(mAb)treatment is prone to selective pressure due to increased possibility of targeted epitope mutation,leading to viral escape.In addition,the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection.These risks can be reduced using multiple mAbs that target nonoverlapping epitopes.Thus,a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.
